Journal Articles
2020

Role of a Pediatric Cardiologist in the COVID-19 Pandemic
T. Niaz
K. Hope
M. Fremed
N. Misra
Zucker School of Medicine at Hofstra/Northwell, nmisra1@northwell.edu

C. Altman

See next page for additional authors

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Pediatrics Commons

Recommended Citation
Niaz T, Hope K, Fremed M, Misra N, Altman C, Glickstein J, Sanchez-de-Toledo J, Fraisse A, Miller J,
Chowdhury D, . Role of a Pediatric Cardiologist in the COVID-19 Pandemic. . 2020 Jan 01; 4():Article 6707
[ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/6707. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic
Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara
Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu.

Authors
T. Niaz, K. Hope, M. Fremed, N. Misra, C. Altman, J. Glickstein, J. Sanchez-de-Toledo, A. Fraisse, J. Miller,
D. Chowdhury, and +2 additional authors

This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/6707

Pediatric Cardiology
https://doi.org/10.1007/s00246-020-02476-y

REVIEW ARTICLE

Role of a Pediatric Cardiologist in the COVID‑19 Pandemic
Talha Niaz1 · Kyle Hope2 · Michael Fremed3 · Nilanjana Misra4 · Carrie Altman2 · Julie Glickstein3 ·
Joan Sanchez‑de‑Toledo5 · Alain Fraisse6 · Jacob Miller7 · Christopher Snyder8 · Jonathan N. Johnson1 ·
Devyani Chowdhury9
Received: 19 August 2020 / Accepted: 26 September 2020
© Springer Science+Business Media, LLC, part of Springer Nature 2020

Abstract
Coronavirus disease 2019 (COVID-19) has affected patients across all age groups, with a wide range of illness severity from
asymptomatic carriers to severe multi-organ dysfunction and death. Although early reports have shown that younger age
groups experience less severe disease than older adults, our understanding of this phenomenon is in continuous evolution.
Recently, a severe multisystem inflammatory syndrome in children (MIS-C), with active or recent COVID-19 infection, has
been increasingly reported. Children with MIS-C may demonstrate signs and symptoms of Kawasaki disease, but also have
some distinct differences. These children have more frequent and severe gastrointestinal symptoms and are more likely to
present with a shock-like presentation. Moreover, they often present with cardiovascular involvement including myocardial
dysfunction, valvulitis, and coronary artery dilation or aneurysms. Here, we present a review of the literature and summary
of our current understanding of cardiovascular involvement in children with COVID-19 or MIS-C and identifying the role
of a pediatric cardiologist in caring for these patients.
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Introduction
A global pandemic was declared by the World Health Organization (WHO) on March 11, 2020 when the coronavirus
disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spiraled into
a global health crisis [1]. COVID-19 has created unprecedented challenges from public health, economic, medical,
and research standpoints. It has been reported across all age
groups and leading to a wide spectrum of illness severity
from asymptomatic carriers to severe multi-organ dysfunction and death. Early observational studies have reported
less severe presentation among children and young adults
as compared to the older adults [2–7]. Rarely, children with
active or recent infection with SARS-CoV-2 can also present
with a severe inflammatory syndrome and features similar
to those encountered in Kawasaki disease [8–11]. In Bergamo province of Italy, a 30-fold increase in the incidence
of Kawasaki-like disease in comparison to the last five years
has been described [8]. As of May 2020, the New York State
Department of Health has also identified over 200 children
with similar presentations [12]. This novel presentation
has been termed as multisystem inflammatory syndrome in
children (MIS-C) [12, 13], or pediatric multisystem inflammatory syndrome (PMIS) [14] or pediatric inflammatory
multisystem syndrome (PIMS) [15]—these terms are used
interchangeably in this article.
With an evolving understanding of this disease and rapidly expanding literature, keeping up with the clinically
relevant information is important to our patients and us
as clinicians. Here we present a summary of our current
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understanding of the role of a pediatric cardiologist in caring
for children and adolescents with COVID-19 and MIS-C.

Case Definitions
COVID‑19
The WHO has proposed case definitions for COVID-19 that
are regularly updated based on new evidence (Table 1) [1,
16]. Generally cases are classified as suspect, probable or
confirmed based on the presence of acute respiratory symptoms, exposure and travel history in addition to confirmatory
COVID-19 testing.

MIS‑C
For children with MIS-C, two current definitions have been
proposed, that may be subject to change as more evidence
becomes available (Table 1). The initial case definition for
MIS-C was proposed by the Royal College of Paediatrics
and Child Health in UK and subsequently accepted by the
WHO, Center for Disease Control and Prevention (CDC)
and European Center for Disease Prevention and Control
[14, 15, 17]. This definition was broad and included children
under the age of 21 years presenting with fever, laboratory
evidence of inflammation, and evidence of clinically severe
illness requiring hospitalization with current or recent history (within 4 weeks) of SARS-CoV-2 infection or exposure. This initial classification was able to identify all the
pediatric patients within a critical spectrum of the disease
that often required intensive care. Nevertheless, a less severe
expression of the disease was also being seen and soon after,
the WHO provided a more inclusive definition recognizing
additional patients who did not require escalation of care.
The age cut off was decreased to 19 years, fever duration of
3 days was introduced in the criteria and a combination of
clinical, laboratory and microbiological criteria were also
introduced in order to embrace all the patients under the
same diagnosis (Table 1) [18].

Differences Between Children and Adults
There are numerous differences between children and adults
with regards to disease prevalence, severity and complications
of COVID-19 (Table 2). The percentage of children affected
by COVID-19 is much lower than adults and they tend to
have milder symptoms and significantly lower morbidity and
mortality [2–7, 14, 19, 20]. Some of the frequently reported
cardiac manifestations of COVID-19 in adults include; myocardial injury, myocardial dysfunction, myocardial infarction,
Takotsubo cardiomyopathy, cardiogenic shock, pericardial
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Table 1  Case definitions of COVID-19 and MIS-C
WHO case definitions of COVID-19
Suspect case
Acute respiratory illness AND a history of travel or residence in a location with community transmission
or contact with a confirmed or probable case of COVID-19 in the last 14 days prior to symptoms OR
exposure to confirmed or probable COVID-19 case in 14 days prior to symptoms onset
OR
Severe acute respiratory illness requiring hospitalization in the absence of alternative diagnosis
Probable case
A suspect case with inconclusive COVID-19 testing or if testing could not be performed for any reason
Confirmed case
Patient with laboratory confirmation of COVID-19 irrespective of clinical signs or symptoms
Illness severity
Mild/moderate No new or increased supplemental oxygen requirement
Severe New or increased supplemental oxygen requirement without needing new or increased non-invasive/invasive mechanical ventilation
Critical New or increased non-invasive/invasive mechanical ventilation requirement OR presence of
sepsis or multi-organ failure or rapidly worsening clinical trajectory
Case definitions of MIS-C
CDC definition
Age < 21 years presenting with fever (38 °C for at least 24 h), laboratory evidence of inflammation and
evidence of clinically severe illness requiring hospitalization with multisystem (> 2) organ involvement
(cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological) with no alternative plausible diagnoses
AND
Positive for current or recent SARS-CoV-2 infection (RT-PCR, serology or antigen test) or COVID-19
exposure within 4 weeks prior to symptoms onset
WHO definition
Age 0–19 years with fever > 3 days AND at least two of the following:
(i) Rash or bilateral non-purulent conjunctivitis or mucocutaneous inflammation
(ii) Hypotension or shock
(iii) Features of myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities (echo findings,
elevated troponin/BNP)
(iv) Evidence of coagulopathy (prolonged PT or PTT, elevated D-Dimer)
(v) Acute gastrointestinal problems (diarrhea, vomiting, or abdominal pain)
AND
Elevated markers of inflammation (ESR, CRP, Procalcitonin) with no other obvious microbial cause of
inflammation
AND
Evidence of COVID-19 (RT-PCR, antigen test or serology positive), or likely contact with patients with
COVID-19
COVID-19 coronavirus disease 2019, MIS-C/PMIS multisystem inflammatory syndrome in children/pediatric multisystem inflammatory syndrome, RT-PCR reverse transcription polymerase chain reaction, SARS-CoV-2 severe acute respiratory syndrome coronavirus

effusion, arrhythmias, and conduction abnormalities, but these
manifestations are quite rare in pediatric patients [21–27]. The
cardiac findings encountered to date in the pediatric population include myocarditis, myocardial dysfunction and coronary artery involvement in MIS-C [8, 10, 12, 28–31]. In adults
patients, comorbidities such as hypertension, diabetes, and
obesity may predispose them to more severe manifestations of
the disease [4, 32, 33]. In children, those that have comorbidities including medical complexity (dependent on technological
support in association with developmental delay and/or genetic
anomalies), obesity and those less than a year of age, seem to
be at a risk for more severe disease [3, 34].

Clinical History and Physical Examination
COVID‑19
A thorough history and physical examination is crucial in
the diagnosis and assessment of a suspected COVID-19
patient. A detailed history of comorbid conditions, history
of exposure to confirmed or probable cases of COVID19 and travel history should be obtained. The most commonly reported symptoms in children are fever and cough
[5, 34–40]. Some children present with gastrointestinal

13

Pediatric Cardiology
Table 2  Difference between adults and children with COVID-19
Adults

Children

Rates of infection
Evidence

High
Low
Chinese Center for Disease Control and Prevention reported only 2% of patients younger than 20 years of age
among 44,672 cases [20]
United States Center for Disease Control and Prevention (CDC) reported only 1.7% children less than 18 years
of age among 149,082 reported cases [7]
Severity of illness
High
Low
Chinese data: 5% of pediatric patients classified as
Evidence
Chinese data: 14% of adult patients classified as
‘severe’ and < 1% as ‘critical’ disease [36]
‘severe’ and 5% as ‘critical’ disease [20]
Italian data: 25% of adult patients classified as ‘severe’ Italian data: 2% of pediatric patients classified as
‘severe’ or ‘critical’ disease [5]
and 5% as ‘critical’ [6]
Complications and mortality High
Low
United States data: Among 46 North American Pediatric
Evidence
United States data: Among 2634 adults hospitalICUs, only 48 children were admitted to intensive care
ized adults in 12 hospitals in New York City, 14%
with a case fatality rate of 4.2% [3]
required intensive care and 12% received mechanical
Chinese data: 1 death [36]
ventilation with a case fatality rate of 21% [4]
Chinese data: Case fatality 2.3% of overall COVID-19 Italian data: No deaths [5]
affected population [20]
Italian data: Case fatality of overall COVID-19
affected population 7% [6]
Potential risk factors leading Hypertension, diabetes, and obesity [4]
Infants < 1 years of age, medical c omplexitya, immune
to severe disease
suppression, obesity [3, 5]
a

Defined as dependence on technological support (tracheostomy with or without ventilator dependence) in association with developmental delay
and/or genetic anomalies

(GI) symptoms including nausea, vomiting, diarrhea or
abdominal pain [34, 41–43]. Some cutaneous manifestations have also been reported in young patients such as
‘pseudo-chilblains’ described as areas of erythema with
vesicles or pustules on hands and feet [44, 45]. Children
with SARS-CoV-2 infection may also be asymptomatic
carriers of the disease [7, 34, 35]. Other reported symptoms in adults include temporary loss of smell (anosmia)
or taste (ageusia) sensation, headaches and thromboembolic phenomena [32, 33, 46–48].

MIS‑C
In children with COVID-19, the latest concern is development of MIS-C, a Kawasaki-like syndrome with signs of
heart failure or shock [8, 10, 12, 17, 49]. In multiple case
series, as high as 50–80% of the children with MIS-C developed signs of systemic hypoperfusion or shock, which is
contrary to Kawasaki disease where only up to 5% of the
cases may require vasopressor support [8–10, 31, 50].
One of the clinical difference between MIS-C and Kawasaki syndrome is a higher incidence of GI symptoms in
MIS-C related to SARS-CoV-2 than with classic Kawasaki disease. These GI symptoms include nausea, vomiting, diarrhea, and/or moderate to severe abdominal pain
sometimes mimicking acute appendicitis or enteritis [10,
31, 50, 51]. In children with MIS-C, there is multisystem
organ involvement including cardiac, renal, hematological,
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or neurological manifestations [8, 10, 12, 17, 31]. Severe
respiratory symptoms are relatively rare in MIS-C [50].
Therefore, children presenting with persistent fever (≥ 38
°C or 100.4°F, ≥ 3 days), gastrointestinal complaints, rash,
conjunctivitis, oral/mucosal changes, or cervical lymphadenopathy require assessment for MIS-C. Signs of heart failure such as edema, organomegaly, murmur, gallop or friction
rub maybe present. It is essential to pay attention to the vital
signs and hydration status of patients. However, MIS-C is
still a rare phenomenon and other sources of infection that
may cause fever or systemic inflammation should also be
considered in differential diagnosis.

Microbiological Diagnosis
There are two categories of tests currently being utilized
for the diagnosis of COVID-19 infection, diagnostic tests
for identifying active infection and serologic tests to identify past infection. Diagnostic tests include direct detection
of SARS-CoV-2 RNA by reverse transcription polymerase
chain reaction (RT-PCR) or detection of SARS-CoV-2 antigens by rapid antigen tests [52]. Detection of viral RNA by
RT-PCR, from nasopharyngeal swab or other upper respiratory tract specimens, is the most commonly used and reliable test [53]. Although RT-PCR is highly specific for the
virus, negative tests should be interpreted with caution as
the specificity of the test depends on the type of assay, site
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and quality of specimen obtained in addition to the timeline
of illness at the time of testing [53, 54]. Rapid antigen tests
are also available for the diagnosis of active infection but
are less commonly used. They are less sensitive than RTPCR but are highly specific for the virus [55]. Serologic
tests detect antibodies (IgM and IgG) to SARS-CoV-2 and
are generally suggestive of a past infection. Serologic tests
demand careful interpretation based on timeline of infection [53].

Laboratory Abnormalities
Common laboratory findings in hospitalized adult patients
with COVID-19 include lymphopenia, neutrophilia, and
elevations of serum amino-transaminases, lactate dehydrogenase (LDH), creatine kinase (CK) and other inflammatory
markers such as C-reactive protein (CRP), procalcitonin, ferritin and erythrocyte sedimentation rate (ESR) [32, 38, 39].
Elevation of troponin and brain natriuretic peptide (BNP)
or N terminal pro BNP (NT-pro-BNP) is associated with
admission to the ICU, intubation, and death in adult patients
[21, 32, 38, 56–60]. These laboratory abnormalities have
also been reported in children, but data are limited due to a
relative lack of studies focused on the pediatric population
[61, 62]. Children presenting with MIS-C consistently demonstrate these laboratory abnormalities including elevated
Troponin and BNP levels [8, 10, 12, 15, 17, 50]. Additionally thrombocytopenia, elevated D-dimer, elevated fibrinogen and hypoalbuminemia may be seen [8–10, 15, 50].

Pathophysiology of Cardiovascular
Manifestations
The etiopathogenesis of cardiovascular manifestations in
COVID-19 are unclear. Several mechanisms have been proposed including direct myocyte injury from viral infection,
myocardial inflammation, myocardial ischemia/infarction,
hypoxia induced apoptosis, microvascular disease, and
cytokine storm [63]. A direct correlation between CRP and
troponin levels has been shown suggesting an additional
inflammatory role in the pathogenesis of the clinical manifestations [60]. Downregulation of the myocardial protective enzyme angiotensin converting enzyme 2 (ACE-2) by
SARS-CoV-2 has also been proposed as a potential mechanism of injury to the myocardium [64]. The mechanism of
coronary artery dilation may be extrapolated from Kawasaki disease and inlammatory vasculopathy [65]. Myocardial
dysfunction, coronary artery involvement, and factors like
hypoxia, electrolyte abnormalities, QT prolonging medications may predispose these patients to various arrhythmias
[66, 67].

Approach to Evaluation and Indications
for Pediatric Cardiology Referral
A general approach towards the evaluation of COVID-19
and MIS-C, as guided by the most recent recommendation
by the CDC and American Academy of Pediatrics (AAP),
is shown in Fig. 1. [14, 17, 68, 69] Pediatric cardiology
may be consulted for patients with COVID-19 with a concern for cardiac involvement or those with MIS-C (Fig. 3).
Presence of chest pain, palpitations, persistent tachycardia,
tachypnea, or new murmurs should prompt further evaluation by laboratory testing, electrocardiogram (ECG) or
echocardiogram. Laboratory evaluation in patients with
significant cardiac symptoms should also include measurement of biomarkers such as troponin or BNP/NT-pro-BNP.
An ECG may be considered in patients with concerning
cardiac symptoms, elevated cardiac biomarkers, or prior to
initiation of any therapy that could prolong the QT interval. Those with elevated troponin and BNP/NT-pro-BNP
may also benefit from an echocardiogram Patients with
cardiogenic and/or distributive shock in the intensive care
should prompt a pediatric cardiology consultation.

Electrocardiographic Abnormalities
and Arrhythmia
Patients affected with COVID-19 or MIS-C may be predisposed to various arrhythmias or electrocardiographic
(ECG) abnormalities, not only from the disease itself but
also from the arrhythmogenic potential of pharmacotherapies. In adults, a higher prevalence of both atrial [38] and
ventricular arrhythmias [59] were noted among hospitalized patients with COVID-19 which has been linked to an
increased risk of in-hospital death [59].
Possible ECG findings in children with COVID-19
or MIS-C are listed in Table 3 and shown in Fig. 2. In
patients with myocardial dysfunction, diffuse ST segment
changes, T wave inversions in lateral leads, low-voltage
QRS, atrioventricular conduction block and sinus node
dysfunction has been reported [26, 70–74]. Premature
ventricular contractions [30], monomorphic [74] or polymorphic ventricular tachycardia (VT) [50] have also been
reported. Patients with MIS-C may present with ECG
abnormalities similar to those expressed in Kawasaki
disease (Table 3) [9, 10]. QT prolongation can be seen in
critically ill patients with systemic inflammation, fever,
electrolyte abnormalities or hypoxia. In addition pharmacotherapies for COVID-19 such as hydroxychloroquine
and azithromycin may cause fatal arrhythmias due to QT
prolongation [75–77]. It is important to obtain a baseline
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Fig. 1  Approach in children with COVID-19 and MIS-C with red flags for pediatric cardiology referral

ECG in patients with COVID-19 to measure a baseline
QT interval, especially in those with congenital long QT
syndrome or other genetic arrhythmias [75, 78–80]. Fever
in patients with COVID-19 may unmask the classic Brugada pattern on ECG [67, 75, 76, 81, 82].
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Table 3  Potential electrocardiographic and echocardiographic findings in MIS-C
Electrocardiographic abnormalities and arrhythmias
Abnormalities related to myocardial dysfunction or myocarditis Diffuse ST segment elevation or depression
T wave abnormality (inversion in lateral leads)
Low QRS voltages
Premature ventricular contractions
Ventricular tachycardia
Abnormalities similar to Kawasaki disease
Non-specific ST and T wave changes
Myocardial ischemia
PR prolongation
Ventricular arrhythmia
Sinus node dysfunction and heart block
Sinus node dysfunction (bradycardia)
PR prolongation
Atrioventricular block
Inherited arrhythmias and sudden death
Prolonged QT
Unmasking of Brugada pattern in patients with underlying Brugada syndrome
in setting of fever
Sudden cardiac death due to fatal arrhythmias
Echocardiographic abnormalities
Ventricles
Depressed function of either or both ventricles, may be severe and may exhibit
global or regional dysfunction
Abnormal myocardial strain
Apical thrombus in setting of severely depressed function
Coronary arteries
Abnormal enhancement of coronary arterial walls
Coronary arterial ectasia or dilation
Aneurysm formation
Thrombus formation in setting of severe coronary dilation
Valves
Valvulitis with valvar insufficiency, particularly the mitral valve
Pericardium
Pericardial effusion
Aortic root
Aortic root dilation

Cardiac Imaging
Echocardiographic Evaluation
During acute COVID-19 infection in hospitalized adult
patients, echocardiographic features supportive of myopericarditis, stress-induced cardiomyopathy, and/or myocardial
ischemia, injury, or infarction have been described [83].
There may be global or segmental mild to severe myocardial
dysfunction involving the left ventricle in isolation or both
ventricles [22, 23]. Left ventricular apical ballooning and
dysfunction consistent with Takotsubo cardiomyopathy [27,
84] as well as pericardial effusions have been reported [22,
23]. In the pediatric population, data are lacking regarding
echocardiographic findings during the acute infection likely
due to the decreased incidence of clinically severe illness
compared with adults [3, 34, 37].
However, echocardiographic information is available
for pediatric patients with MIS-C. The initial alert to the
international community first identifying MIS-C described
myocarditis, valvulitis, pericardial effusion, and coronary
artery dilation as features of the disease [14]. Of the 8 children from the United Kingdom (UK) reported by Riphagen

et al., ventricular dysfunction was present in 6 patients.
Only 1 child had severely dilated coronaries and 1 had pericoronary echogenicity [9]. Subsequently, Belhhadjer et al.
reported data regarding 35 children with MIS-C with acute
left ventricular dysfunction (68% with cardiogenic shock)
[10]. One of these patients had localized akinesis of the
apical segment consistent with Takotsubo cardiomyopathy.
Fortunately, 71% recovered LV function fully by day 7 of illness with therapy [10]. Coronary artery dilation (Z score > 2)
was present in only 17% and pericardial effusions were seen
in 8%. Verdoni et al. reported 10 patients with features of
typical or atypical Kawasaki Disease and COVID-19, with
ventricular dysfunction (ejection fraction < 55%) in 5, mitral
insufficiency in 4 and coronary aneurysms (> 4 mm) in 2
patients [8]. Most recently, Whittaker et al. reported on 55
children from 8 hospitals in the UK who underwent echocardiography. Coronary dilation (Z score > 2) was noted in
8 (14%), including 2 with giant aneurysms (Z scores > 10).
Of these eight, five had shock alone, one with fever and
inflammation, and two with some mucocutaneous features
of Kawasaki disease. Of the 29 children with shock, 62% had
LV dysfunction on echo [50]. In a recent study from US constituting 186 children with MIS-C, Feldstein et al. reported
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Fig. 2  Electrocardiographic
abnormalities in children
with COVID-19 and MIS-C.
a Low-voltage QRS complex
in a patient with myocarditis.
b Complete heart block in a
patient with myocarditis. c ST
segment changes in anterior
leads suggestive of anterior
infarction in a patient with giant
coronary artery aneurysms and
thrombosis

coronary artery aneurysm (Z score > 2.5) in 9% (15/170) of
the children who had echocardiogram [31].
For pediatric patients presenting with concern for MIS-C,
hemodynamic shock and/or features of classic or atypical
Kawasaki disease, a careful echocardiographic assessment
(Table 3; Fig. 3) of left and right ventricular function, the
pericardium, coronary arteries, and cardiac valves should be
performed on admission to establish a baseline, as well as to
guide initial vasoactive management for patients presenting
with features of shock. It is important that the individual
performing the echo have the skills to obtain all the necessary images in a time efficient manner to limit exposure. The
American Society of Echocardiography (ASE) statement
regarding echocardiography services during the COVID-19
pandemic can serve as a useful reference with regards to
best practices [85]. The optimal interval between echocardiographic assessments remains to be determined. Primarily, a
change in clinical status should guide the echocardiographic
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evaluation in individual cases. For patients requiring ICU
management, daily echocardiograms may be warranted
given the potential for rapid changes. For those on acute
care floors, repeat echocardiograms every 2–3 days may be
helpful although should be guided by the clinical scenario.
Serial echocardiographic assessment of the coronary arteries
for evolving dilation or development of coronary aneurysms
is important as well, as this will impact decisions regarding
immunomodulatory therapies and anti-thrombotic regimens.
Previously published guidelines for optimal coronary artery
imaging in Kawasaki Disease can be utilized [65, 86]. For
patients with severe ventricular dysfunction or severe coronary dilation, serial assessment for thrombus is important.
All MIS-C or Kawasaki disease spectrum type patients
should have a follow-up with a pediatric cardiologist with
an echocardiogram. Timing of follow-up and imaging tests
will depend upon the clinical course, as well as the type
and severity of cardiac involvement. Long term outcomes
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Fig. 3  Echocardiographic abnormalities in children with COVID-19
and MIS-C. a Parasternal short axis view at the level of aortic valve
demonstrating diffuse dilation of right coronary artery (RCA) and
coronary artery walls are echogenic. b Apical 4 chamber view demonstrating mitral valve regurgitation. c Parasternal short axis view at

the level of mitral valve showing tiny posterior pericardial effusion
in a patient with myocarditis. d M-mode demonstrating decreased
systolic function. e Apical 4 chamber view demonstrating severe left
ventricular (LV) dilation due to myocardial dysfunction

of children with MIS-C are unknown. Patients with continued coronary artery abnormalities or depressed ventricular
function should continue to follow with a pediatric cardiologist while these sequelae of MIS-C are present. Given the
unknowns, even those with recovery of ventricular function
or resolution of coronary dilation likely warrant continued
follow-up over time.

poor acoustic windows limit echocardiographic assessment. Similar to Kawasaki disease, CTA also plays an
important role in assessing distal vessels for evidence
of dilation [65]. CTA is also critical in the evaluation of
suspected coronary thrombus. Data regarding the use of
cardiac magnetic resonance (CMR) imaging in the pediatric age group with COVID-19 are lacking although utilization of CMR imaging can be guided by previous evidence from viral myocarditis. Decisions should be made
on case by case basis in consideration with the pediatric
cardiologist. In the adult population, the utility of CMR
has been described in a case report of myocarditis due to
COVID-19, where it was used to confirm the diagnosis

Advanced Imaging
Advanced cardiac imaging with computed tomographic
angiography (CTA) may be necessary for demonstration
of coronary arteries in older children and adolescents if
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Table 4  Considerations for management of children with COVID-19 or MIS-C and cardiovascular involvement
Considerations for management of typical COVID-19 with cardiovascular involvement
General considerations
Supplemental oxygen, non-invasive or invasive mechanical ventilation
may be needed for patients as appropriate
Fluid replenishment and adequate electrolyte monitoring
Empiric antibiotics as clinically appropriate
Antiviral therapies are to be used in the settings of a clinical trial in
discussion with an infectious disease team
Cardiac considerations
For myocardial dysfunction, arrhythmias or other manifestations, see
management suggestions listed below
Considerations for management of MIS-C with cardiovascular involvement
General considerations
Level of care is determined by the severity of illness
Given multisystem involvement, patients may benefit from care by a
multidisciplinary team of specialists
Sequential laboratory markers of inflammation, coagulation studies,
liver function tests and cardiac biomarkers may be warranted in hospitalized patients
Additional management, as appropriate, is as per the intensivist or
hospitalist based on the clinical presentation
Myocardial dysfunction or myocarditis
Serial laboratory monitoring of cardiac biomarkers including troponin
and BNP/NT-pro-BNP
Serial echocardiographic assessment of myocardial function
Continuous cardiac monitoring for arrhythmias
Hemodynamic support utilizing inotropes and ECMO as indicated
Care should be taken while sedating or intubating patients with severely
depressed ventricular function
Consideration for therapies such as IVIG, steroids or biological agents
in the setting of a multidisciplinary team discussion regarding current
evidence and best practices, risks and benefits
Arrhythmias
12 lead ECG may obtained in all hospitalized children, those with
elevated cardiac biomarkers or cardiac symptoms and before initiating
any QT prolonging pharmacotherapies
Aggressive fever reduction with acetaminophen is necessary for patients
with Brugada syndrome
Aggressive electrolyte correction is necessary for patients with inherited
arrhythmias and channelopathies
Modified ACLS and BLS guidelines should be utilized during cardiopulmonary resuscitation
Coronary artery and thrombotic complications
Antiplatelet therapy should be considered for patients with MIS-C
Anticoagulation guided by Kawasaki guidelines can be utilized based
on degree of coronary artery involvement
Pediatric cardiology follow-up and serial echocardiographic assessment
is critically important for patients with coronary artery dilation due to
MIS-C
Considerations for children with underlying cardiovascular conditions
Chronic medications
Continue ACE inhibitors or ARBs in patients who are chronically
receiving these therapies for hypertension, heart failure or other
underlying diseases [66]
Anticoagulation
Certain exploratory antiviral therapies such as ropinavir/ritonavir,
ribavirin, and adjunctive therapies such as sarilumab, tocilizumab
interferon and methylprednisolone may interact with Warfarin.
Therefore adequate INR monitoring should be performed with these
therapies [66]
Aspirin should be continued in children and adolescents on chronic
therapy for their underlying cardiovascular condition
Immunosuppression
There is insufficient evidence regarding the potential role of reduction
or changes in T-cell immunosuppressive therapy among infected
patients after cardiac transplant patients with COVID-19. A detailed
discussion with cardiac transplant team weighing risks and benefits of
reduction in T-cell immunosuppression is warranted [16]
ACE angiotensin converting enzyme, ARBs angiotensin receptor blockers, ACLS advanced cardiac life support, BLS basic life support, BNP
brain natriuretic peptide, INR international normalized ratio, MIS-C multisystem inflammatory syndrome in children
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and to demonstrate the extent and severity of myocardial
edema [30].

Management of Cardiovascular
Complications in COVID‑19
General Considerations
COVID-19 can lead to a wide spectrum of illness severity
(Table 1) which guides the management [16]. Some general
considerations for management of COVID-19 patients are
stated in Table 4. The efficacy of various antiviral therapies
in COVID-19 has yet to be established [16]. Therefore until
more evidence is available; therapies such as remdesivir and
hydroxychloroquine should be used in context of a clinical
trial while weighing the risks and benefits of the therapy
[16]. These decisions are individualized to every patient
keeping in consideration the various risk factors including
young age, immunocompromised status, underlying cardiac
or pulmonary disease, obesity or diabetes [16].

Approach to Cardiovascular Complications
Myocardial Injury and Myocarditis
Although myocardial dysfunction is uncommon among children with typical COVID-19 infection; children presenting
with MIS-C may have significant myocardial involvement
[8–10, 50]. Evidence regarding optimal management of
myocardial injury in patients with COVID-19 is limited.
The management may be guided by the extent of myocardial injury based on laboratory (elevated Troponin or BNP/
NT-pro-BNP) and imaging (echocardiography or CMR)
Table 5  Evidence on utilization
of intravenous immune globulin
and steroids in MIS-C
Belhadjer et al. [10]
(France and Switzerland)
Riphagen et al. [9]
(United Kingdom)
Verdoni et al. [8]
(Italy)
Cheung et al. [87]
(United States)
Whittaker et al. [50]
(England)
Feldstein et al. [31]
(United States)
Combined studies

assessment. Serial monitoring of biomarkers is prudent during admission as detailed in the section on laboratory evaluation. Hemodynamically stable children with mild myocardial
dysfunction should be medically managed and optimized
with careful fluid resuscitation, diuretics and heart failure
therapy as appropriate. Children with hemodynamically significant or severe myocardial dysfunction may require inotropic support, mechanical ventilation to reduce metabolic
demand and mechanical circulatory support with extracorporeal membrane oxygenation (ECMO) in those with critical hemodynamic compromise [10]. Shock in patients with
MIS-C is often vasoplegic rather than cardiogenic and the
use of norepinehrine to treat is effective but treatment may
be guided by the degree of ventricular dysfunction [9].
Children with MISC and myocardial dysfunction may
warrant treatment with intravenous immunoglobulin (IVIG)
and/or steroids although the evidence is currently limited
(Table 5) [8–10, 50, 87]. In six case series constituting
314 patients with MIS-C or Kawasaki-like presentation, a
majority of patients were initially treated with IVIG (77%,
241/314) with or without steroids (53%, 167/314) [8–10, 50,
87]. Other immunomodulatory agents like anakinara was
used in 20 patients, 8 received infliximab and 1 received
tocilizumab. Among studies with available data, almost half
of the patients (50%, 64/128) received combined therapy
with at least 2 immunomodulatory agents generally IVIG
and steroids.
Arrhythmias
Although arrhythmias may be a rare manifestation of
COVID-19, they are not uncommon in critically ill children
with COVID-19 and MIS-C [9, 10, 75]. Critically ill patients
with COVID-19 or MIS-C requiring intensive care or those

Total No of Pts

IVIG

Steroids

Others

Combined
therapy (≥ 2
agents)

35

71% (25)

34% (12)

Anakinara (3)

14% (5)

8

100% (8)

62% (5)

None

62% (5)

10

100% (10)

80% (8)

None

80% (8)

17

76% (13)

82% (14)

Tocilizumab (1)

65% (11)

58

70% (41)

64% (37)

60% (35)

186

77% (144)

49% (91)

Anakinara (3)
Infliximab (8)
Anakinara (14)

314

77% (241)

53% (167)

50% (64)

Values are reported as % (n)
IVIG intravenous immune globulin
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with increased arrhythmia risk should be placed on continuous ECG monitoring [76]. Management should be tailored
to the individual patient and arrhythmia. For instance in
patients with Brugada syndrome, aggressive fever reduction with acetaminophen is prudent [77]. General considerations for management of arrhythmias are stated in Table 4.
Additionally, the American Heart Association has released
interim guidelines for basic and advanced life support in
adults, children, and neonates with suspected or confirmed
COVID-19 with attention to reducing provider exposure,
prioritizing oxygenation and ventilation strategies, and considering the appropriateness of resuscitation [88].
Thrombotic Complications
Considering similarities between MIS-C and Kawasaki disease, these patients may also be at a higher risk of thrombotic complications. Among combined 278 patients from
five recent studies who had echocardiograms, coronary dilation or aneurysm was reported in 12% (132/278) of patients
[8, 10, 12]. Therefore, patients with MIS-C who fulfill criteria for Kawasaki disease, whether complete or incomplete,
should be treated with appropriate anti-thrombotic therapy
based on the degree of coronary artery involvement. Antiplatelet therapy should also be considered for all patients
with MIS-C and evidence of coronary artery involvement
[65]. Similarly patients with significant left ventricular dysfunction should also receive systemic anticoagulation as
appropriate [89].

Pre‑existing Cardiovascular Conditions
Children with congenital heart diseases or underlying cardiovascular conditions such as hypertension, heart failure
or cardiac transplant pose certain unique challenges to their
providers. It is critical to pay attention to their underlying
disease process and chronic medications [16, 66]. Currently
there is insufficient evidence to suggest any concern around
safety of ACE inhibitors or Angiotensin receptor blockers
(ARBs) in patients with COVID-19. Therefore multiple
societies have endorsed and recommended to continue ACE
inhibitors or ARBs therapy in patients who are chronically
receiving these therapies for hypertension, heart failure or
other underlying diseases [66]. Certain exploratory antiviral therapies like ropinavir/ritonavir, ribavirin, sarilumab,
tocilizumab and adjunctive therapies like interferon or methylprednisolone may interact with Warfarin [66]. Therefore
patients on chronic anticoagulation therapy should have
adequate monitoring of INR while pursuing these therapies. Aspirin should be continued in children and adolescents on chronic therapy for their underlying cardiovascular
condition. Currently there is insufficient evidence regarding
role of reduction or changes in T-cell immunosuppressive
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therapy among infected patients after cardiac transplant [16].
A detailed discussion with cardiac transplant team weighing
risks and benefits of reduction in T-cell immunosuppression
is warranted.

Outcome and Follow‑up
In a recent study by Feldstein et al. constituting 186 children from US, 8 patients required ECMO and 4 deaths
were reported [31]. Among 230 cases of suspected MIS-C
associated with COVID-19 reported to European Centre for
Disease Prevention and Control, at least two deaths have
been reported [11]. Currently we do not have enough data
to predict future complications in MIS-C associated with
COVID-19. As we steer through this uncharted territory of
COVID-19, we may have to extrapolate evidence from conditions with similar presentations such as viral myocarditis
or Kawasaki disease. Recommendations for follow-up, long
term anticoagulation return to school and sports participation should be individualized to every patient. Follow-up
should be individualized based on the degree of myocardial
dysfunction, arrhythmia burden, and cardiac biomarkers
along with a potential role of advanced imaging with CMR,
as per the guidelines by AHA and American College of Cardiology (ACC) [90, 91].

Cardiac Interventions
The COVID-19 pandemic has seriously affected surgical and interventional practices, both catheterization and
electrophysiology, in pediatric and congenital cardiology
[92, 93]. Majority of centers have canceled or rescheduled
elective procedures during the first phase of the pandemic
and utilized a multidisciplinary committee to determine the
candidacy of patients for urgent or emergent procedures.
The definition of elective, urgent or emergent procedures
is dependent on institutional policy and various society
guidelines are now available to guide decisions [93, 94].
Generally, procedures are considered urgent or emergent if
there is a substantial risk of clinical decompensation, hospitalization, or death if procedures are not performed [93, 94].
It is necessary to maintain a focus on resource utilization,
preservation of medical supplies and minimization of exposure to hospital staff and other patients while making these
decisions [92]. Pre-procedural COVID-19 testing is being
performed in many centers to ensure safety and adequate
personal protective equipment (PPE) utilization by health
care team. Recommendations related to PPE continue to
change. There is a concern that there may be a backlog of
purely elective cases, a so called “surge after the surge”, that
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may continue on for months [95]. Each program should have
a plan on how to deal with these cases [95].

Impact on the Economy and Insurance
Policies
The negative effects of the COVID-19 pandemic on our
national and global economy have been dramatic, affecting almost every industry. The majority of health insurance
companies have followed the lead of the federal government
and Centers for Medicare and Medicaid Services (CMS) to
rapidly expand coverage to patients with COVID-19. All
testing for COVID-19 has been designated an Essential
Health Benefit (EHB), meaning it is to be covered by all
Affordable Care Act—compliant plans. In March 2020, Congress passed the Families First Coronavirus Response Act
[96] which requires the majority of private health plans to
cover COVID-19 testing and all related urgent care center
and emergency room visits, telehealth services, and in-person medical provider encounters, all with no cost sharing
(co-payments, co-insurance and deductibles) and no prior
authorization during the emergency period [96]. There continue to be discrepancies across states and insurance policies, so it is advised that the patient, physician and billing
department stay abreast of this rapidly changing market and
their implications. If patients are experiencing financial difficulties due to COVID-19, there are a number of government
programs available, including but not limited to unemployment coverage:Supplemental Nutrition Assistance Program
(SNAP), Women, Infants, and Children (WIC), Child’s
Health Insurance Program (CHIP) and Medicaid. For children, the CHIP offers free or low-cost medical and dental
care to uninsured patients through 19 years of age, whose
family income is above Medicaid’s limit but below their
state’s CHIP limit. Many states have modified their CHIP
enrollment criteria and dates to expand eligibility and eliminate or waive premiums. The CARES act and SBA loans
have provided some financial support to medical practices
and hospitals.

Future Directions
COVID-19 has had a profound impact on the practice of
medicine and will continue to impact all elements of patient
care. As more pediatric data become available, the approach
to the evaluation and management of children with COVID19, including those with suspicion for cardiac injury, will
necessarily evolve. Pediatric cardiologists can have a meaningful impact in the care and outcomes of these patients.
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